Press Release 

DCAT Welcomes Five New Member Companies

Robbinsville, NJ, January 19, 2010 – – The Drug, Chemical and Associated Technology Association (DCAT), the PharmaChem industry’s premier business development association, is pleased to announce the addition of the following new member companies: Biovail Contract Research, Concord Biotech Limited, Hisun Pharmaceutical Co., Neos Therapeutics and Samyang Genex Corporation.  To learn about other DCAT member companies, visit DCAT’s Meet Our Members.

Biovail Contract Research
Biovail Contract Research is a full service Canadian CRO that has been conducting early phase clinical trials since 1975. We have completed over 3,000 studies in healthy & special populations. There are six clinics configurable for up to 194 beds, including dedicated first-in-human (FIH) facilities. Our bioanalytical laboratory features the latest equipment & technologies and offers more than 195 validated methods. Developing methods with the lowest LOQ and rapid turnaround timelines is our commitment. We provide scientific input before, during and after a clinical trial, including generation of study designs, protocols, statistical analysis, data management & final reports.

Concord Biotech Limited
Concord Biotech Limited is an R&D based biotechnology company with a USFDA inspected state-of-the-art fermentation facility. Concord manufactures fermentation & semi-synthetic based APIs in the area of enzyme, statins, immunosuppressants, and antibiotics, etc. Concord also initiated CRAM activities, for global giants in the area of strain improvement, biotransformation, secondary metabolites, etc.  

Hisun Pharmaceutical Co.
Zhejiang Hisun Pharmaceutical Co. Ltd. located in Taizhou Zhejiang, a coastal city in southeastern China, was founded in 1956. Hisun has become a leading API manufacturer in China. Product range includes a series of medicines for oncology, cardiovascular, anti-infection, hypoglycemic, anti-parasite, endocrine regulation, immunosuppressant, antidepressant and human & animal health, etc. Over 80% of sales revenue comes from exporting to more than 30 countries and regions in both Europe and America.
Since 1989, Hisun has started regulatory registration in US and European markets. Hisun got its first FDA approval in 1992. FDA officials have come to Hisun ten times, and Hisun also accepted authority audits of European Union, Germany, England, Japan, Korea and Australia successfully. So far, 20 products have FDA approval, 17 products have CEP certificate and, 4 products have been approved by Japanese Authority ( PMDA).

Hisun has about 4000 employees, one third of them are scientific and technical personnel. In year 2000, Hisun was listed as a public company in Shanghai A share Stock Exchange. As one of the biggest manufacturing bases of antibiotics and oncology products, Hisun is devoted to provide better service to global clients with its strong R&D resources.

Neos Therapeutics
Neos Therapeutics is a value-added partner in the development and manufacture of dietary supplements, OTC's, and medical foods. Neos has various proprietary technologies that provide our customers and licensees with a unique position in the market.  

Samyang Genex Corporation
Samyang Genex Corporation is well known for its worldwide GMP manufacturing facility with certifications. We manufacture APIs such as Paclitaxel, Docetaxel, Epothilone, and Vancomycin HCl. We operate oncology-dedicated injectable manufacturing facility producing Paclitaxel (generic/cremophor-free formulation), Oxaliplatin, Gemcitabine, Docetaxel (generic/cremophor-free formulation). Octreotide and Exenatide are being developed as well.

About DCAT
DCAT is the premier business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, nutritional and related industries.

Erin Sanders
DCAT Communications Coordinator